Ebastine provides relief from Irritable Bowel Syndrome

In a study published today by Gastroenterology, we demonstrate in a randomized placebo controlled trial that the anti-histimine Ebastine provides relief from the symptoms of Irritable Bowel Syndrome (IBS). The study, led by Prof Guy Boeckxstaens and in collaboration with the Translational Immunology Laboratory, tested the effect of Ebastine on pain relief. Over a 12 week course, nearly 50% of IBS patients showed considerable relief from symptoms. As Ebastine is a safe over-the-counter anti-histimine, commonly prescribed for allergy, this study could be rapidly extended to millions of IBS patients across the world.

Read more: Wouters et al. 'Histamine Receptor H1-mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome'. Gastroenterology. 2016